Biotech
Monday, March 25th, 2024 4:11 pm EDT
Key Points
- Amgen’s innovative approach in the weight loss drug market involves testing an injectable treatment called MariTide, which offers a unique mechanism compared to existing medications from Novo Nordisk and Eli Lilly.
- MariTide, administered once a month or even less frequently, shows promise in both aiding weight loss and maintaining it after treatment cessation, potentially offering greater convenience and effectiveness compared to weekly injections.
- Amgen’s ongoing phase two trial aims to provide further clarity on MariTide’s efficacy, safety, and dosing regimens, with initial results expected later this year, potentially challenging the dominance of established players in the weight loss drug space.
Amgen is taking a pioneering approach in the competitive realm of weight loss drug development with its experimental treatment, MariTide, which offers a distinct mechanism from existing medications like Wegovy and Zepbound. MariTide, administered through monthly injections, not only aids in weight loss by activating gut hormone receptor GLP-1 but also uniquely blocks GIP, offering potential advantages in sustained weight loss even after treatment cessation. While Novo Nordisk and Eli Lilly currently dominate the weight loss drug market, analysts project significant growth, attracting new contenders like Amgen. Early-stage trial data on MariTide demonstrates promising results, with patients experiencing substantial weight loss and maintaining it post-treatment. However, further research is required to ascertain its efficacy and safety, particularly in comparison to existing treatments. Amgen’s ongoing phase two trial aims to address these questions, exploring optimal dosing regimens and long-term effects, which will provide valuable insights into MariTide’s potential to disrupt the weight loss drug landscape.
For the full original article on CNBC, please click here: https://www.cnbc.com/2024/03/24/amgen-aims-to-enter-weight-loss-drug-market-with-a-new-approach.html
